Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

4

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

GABA-A receptor; agonist GABA site

3

Transient receptor potential cation channel subfamily A member 1

3

Transient receptor potential cation channel subfamily M member 8

3

Transient receptor potential cation channel subfamily V member 3

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase I

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2000

3

Unknown

2

1994

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Postoperative pain

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

EPA CompTox

5

MERCK INDEX

5

PUBCHEM

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PINOSYLVIN

881R434AIB

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

BORNEOL

M89NIB437X

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2000

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

GABA-A receptor; agonist GABA site

Transient receptor potential cation channel subfamily M member 8

Transient receptor potential cation channel subfamily A member 1

Transient receptor potential cation channel subfamily V member 3

Conditions:

Postoperative pain

Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of born...

eol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.

TROPOLONE

7L6DL16P1T

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1994

Class (Stereo):

CHEMICAL (ACHIRAL)

3,5-STILBENEDIOL, (Z)-

SUT6G9WH0N

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

ISOBORNEOL, (+)-

8GDX32M6KF

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2000

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

GABA-A receptor; agonist GABA site

Transient receptor potential cation channel subfamily M member 8

Transient receptor potential cation channel subfamily A member 1

Transient receptor potential cation channel subfamily V member 3

Conditions:

Postoperative pain

Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of born...

eol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.

Dexborneol

8D24LWT4FK

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2000

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

GABA-A receptor; agonist GABA site

Transient receptor potential cation channel subfamily M member 8

Transient receptor potential cation channel subfamily A member 1

Transient receptor potential cation channel subfamily V member 3

Conditions:

Postoperative pain

Borneol, a monoterpenoid alcohol, is a component of many essential oils. Barneol occurs in nature as a single enantiomer (d- or l-, depending on the oil type) or, less frequently, as the racemate. Several studies have proved the effectiveness of born...

eol. In Chinese medicines borneol has been used in relieving symptoms of anxiety, fatigue and insomnia; inducing anesthesia and analgesia to alleviate abdominal pain, wounds and burns; relieving rheumatic pain, hemorrhoids, skin diseases and ulcerations of the mouth, ears, eyes or nose; to treat sore throats and skin infections, and is mainly used to treat cardiovascular and cerebrovascular diseases. Borneol has a significant therapeutic effect on neuralgia. This compound is considered a GRAS approved by the FDA as food flavor. Additionally, borneol is a fragrance ingredient. GABAA, TRPV3, TRPM8 and TRPA1 have been identified as the molecular targets of borneol.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1